Syra Health Corp (SYRA) 2024 Q3 法說會逐字稿

Good morning, everyone, and thank you for joining us for Syra Health's third quarter 2024 financial results conference call. My name is Robert Blum, and I will be your moderator for today's event. Joining us on today's call is Dr. Deepika Vuppalanchi, CEO of Syra Health; and Priya Prasad, Syra's Chief Financial Officer.

大家早安，感謝您參加 Syra Health 2024 年第三季財務業績電話會議。我叫羅伯特‧布魯姆，我將擔任今天活動的主持人。加入我們今天電話會議的是 Syra Health 執行長 Deepika Vuppalanchi 博士；以及 Syra 財務長 Priya Prasad。

At the conclusion of today's prepared remarks, management will answer some questions that were sent to us by investors and other questions we think are relevant to investors as well. Today's event is being recorded and will be available for replay through the webcast information provided in the press release.

在今天準備好的發言結束時，管理層將回答投資者向我們提出的一些問題以及我們認為也與投資者相關的其他問題。今天的活動正在錄製中，並將透過新聞稿中提供的網路廣播資訊重播。

I'd also like to call to your attention the customary safe harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations and future potential operating results of Syra Health.

我還想提請您注意有關前瞻性資訊的慣例安全港披露。今天的電話會議將包含某些前瞻性聲明，包括有關 Syra Health 的目標、策略、信念、期望和未來潛在營運績效的聲明。

Although management believes these statements are reasonable based on estimates, assumptions and projections as of today. These statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay.

儘管管理階層認為這些陳述基於截至目前的估計、假設和預測是合理的。這些陳述並不是對未來業績的保證。時間敏感資訊在任何電話或網路廣播重播時可能不再準確。

Actual results may differ materially as a result of risks, uncertainties and other factors including, but not limited to the factors set forth in the company's filings with the SEC. Syra undertakes no obligation to update or revise any of these forward-looking statements.

由於風險、不確定性和其他因素（包括但不限於公司向 SEC 提交的文件中列出的因素），實際結果可能會存在重大差異。Syra 不承擔更新或修改任何這些前瞻性聲明的義務。

With that said, I would like to turn the event over to Dr. Deepika Vuppalanchi, Chief Executive Officer of Syra Health. Deepika please go ahead.

話雖如此，我想將這次活動交給 Syra Health 執行長 Deepika Vuppalanchi 博士。迪皮卡請繼續。

Thank you, Robert. Welcome, everyone. Thank you for joining our third quarter earnings call today. We truly appreciate your continued interest in Syra Health and are excited to share updates on the recent performance and future goals. I will begin by highlighting our strong third quarter financial performance, followed by an update on the strategic cost-cutting initiatives we have successfully implemented.

謝謝你，羅伯特。歡迎大家。感謝您今天參加我們的第三季財報電話會議。我們衷心感謝您對 Syra Health 的持續關注，並很高興分享有關近期業績和未來目標的最新資訊。我將首先強調我們強勁的第三季財務業績，然後介紹我們已成功實施的策略成本削減措施的最新情況。

After that, I will outline the significant strides we are making on a journey towards profitability. Then I will hand over the call to our Chief Financial Officer, Priya Prasad, who will take you through a more detailed breakdown of our financial results.

之後，我將概述我們在實現盈利的過程中所取得的重大進展。然後我會將電話轉交給我們的財務長 Priya Prasad，他將向您詳細介紹我們的財務表現。

In terms of financial metrics, we have experienced significant positive shifts across the board. The third quarter on an outstanding period for Syra Health with revenues growing by a notable 42% compared to the same period last year. This robust performance was driven primarily by our high-margin Population Health business unit, which has seen sustained demand for its data analytics, epidemiology and health equity services, alongside strong contributions from our legacy Healthcare Workforce business, which continues to perform above expectations.

就財務指標而言，我們全面經歷了重大的正向轉變。Syra Health 第三季表現出色，營收與去年同期相比顯著成長 42%。這種強勁的業績主要是由我們的高利潤人口健康業務部門推動的，該部門對其數據分析、流行病學和健康公平服務的持續需求，以及我們傳統的醫療保健勞動力業務的強勁貢獻，該業務的表現持續高於預期。

This growth underscores the strength of a diversified business model and the ability to capitalize on opportunities in both established and emerging sectors.

這種成長凸顯了多元化業務模式的優勢以及利用成熟和新興產業機會的能力。

The gross profit margin was 30% in third quarter of 2024 compared to 35% in the previous year, primarily due to the timing of the implementation cycle versus revenue recognition for certain milestone-driven projects. Total revenue experienced an increase of 14.4% and compared to the previous quarter, showcasing a strong growth trajectory.

2024 年第三季的毛利率為 30%，而前一年為 35%，這主要是由於實施週期的時間安排與某些里程碑驅動專案的收入確認有關。總營收較上一季成長 14.4%，展現出強勁的成長軌跡。

Additionally, our gross profit margin improved notably, rising by 1,190 basis points compared to second quarter of 2024, reflecting our commitment to operational efficiency and profitability. Additionally, the strategic focus on high-margin offerings has allowed us to drive operational efficiencies, further solidifying our financial foundation.

此外，我們的毛利率顯著提高，與 2024 年第二季相比上升了 1,190 個基點，反映了我們對營運效率和獲利能力的承諾。此外，對高利潤產品的策略重點使我們能夠提高營運效率，進一步鞏固我們的財務基礎。

These gains not only reflect our ability to deliver value, but also support our long-term growth strategy as we scale our operations and enter new markets, including federal and global mental health initiatives.

這些收益不僅反映了我們創造價值的能力，而且隨著我們擴大業務規模和進入新市場（包括聯邦和全球心理健康計劃），也支持我們的長期成長策略。

We are also seeing strong demand for our Syrenity app in the mental and behavioral health space, signaling potential for exponential growth in these rapidly expanding markets. With the combination of revenue growth, cost optimization and our focus on innovative solutions we are confident in our path forward and remain laser focused on achieving profitability in the near future.

我們也看到心理和行為健康領域對 Syrenity 應用程式的強勁需求，這表明這些快速擴張的市場具有指數成長的潛力。透過收入成長、成本優化以及對創新解決方案的關注，我們對前進的道路充滿信心，並繼續專注於在不久的將來實現盈利。

We are confident in our growth trajectory and remain focused on achieving profitability in 2025, by emphasizing excellence in commercial, operational and innovation strategies. Beginning with our emphasis on commercial excellence, we have committed to boosting our revenue and enhancing our profit margins by expanding our portfolio of high revenue clients.

我們對自己的成長軌跡充滿信心，並繼續致力於透過強調卓越的商業、營運和創新策略，在 2025 年實現盈利。從我們對商業卓越的重視開始，我們致力於透過擴大我們的高收入客戶組合來增加我們的收入並提高我們的利潤率。

This strategy not only improves our profitability but also underscores our dedication to delivering greater value to our shareholders. Larger clients significantly contribute to our bottom line through high contract values, economies of scale and reduced sales and marketing costs. They provide stability and predictability in revenue, create opportunities for cross-selling and enhance our brand reputation.

這項策略不僅提高了我們的獲利能力，也強調了我們致力於為股東創造更大價值的決心。大客戶透過高合約價值、規模經濟以及降低的銷售和行銷成本為我們的利潤做出了重大貢獻。它們提供了收入的穩定性和可預測性，創造了交叉銷售機會並提高了我們的品牌聲譽。

By serving these large clients, we can drive innovation and develop new high-margin products and services, ultimately reinforcing our commitment to maximizing shareholder value.

透過為這些大客戶提供服務，我們可以推動創新並開發新的高利潤產品和服務，最終強化我們對股東價值最大化的承諾。

Shifting our focus to operational excellence, I want to emphasize that the recent cost-cutting measures have not impacted our revenue production. As you may recall, in the second quarter, we announced a restructuring aimed at reducing operating expenses. Over the past few months, we have made strategic adjustments to our workforce to optimize efficiency and lower costs without compromising our revenue-generating capabilities.

將我們的重點轉向卓越運營，我想強調的是，最近的成本削減措施並沒有影響我們的收入生產。您可能還記得，在第二季度，我們宣布了旨在減少營運費用的重組。在過去的幾個月裡，我們對員工隊伍進行了策略調整，以在不影響創收能力的情況下優化效率並降低成本。

In fact, our net loss for the third quarter of 2024 was a remarkable 69% reduction from the net loss in the second quarter of 2024. These efforts have significantly improved our financial metrics, and we have committed to further stabilizing our operational expense ratio. This enhancement highlights our dedication to efficiency and cost management, which ultimately allows us to allocate more resources towards growth initiatives.

事實上，我們 2024 年第三季的淨虧損比 2024 年第二季的淨虧損大幅減少了 69%。這些努力顯著改善了我們的財務指標，我們致力於進一步穩定我們的營運費用率。這項增強凸顯了我們對效率和成本管理的奉獻，這最終使我們能夠為成長計畫分配更多資源。

In our pursuit of innovation excellence, we are focused on expanding our innovation pipeline to enhance the variety of products and services we provide. This includes our Mental Health product, Syrenity, which is designed to offer effective solutions for behavior health challenges.

在追求卓越創新的過程中，我們致力於擴大我們的創新管道，以增強我們提供的產品和服務的多樣性。這包括我們的心理健康產品 Syrenity，該產品旨在為行為健康挑戰提供有效的解決方案。

We are also developing Syra Health AI guard rates for chat bots and AI agents, ensuring safe and responsible AI interactions in health care. Additionally, we are committed to deliver a comprehensive large-scale health education programs that facilitate healthcare workforce development.

我們也正在為聊天機器人和人工智慧代理開發 Syra Health AI 防護率，確保醫療保健領域安全和負責任的人工智慧互動。此外，我們致力於提供全面的大規模健康教育計劃，以促進醫療保健勞動力的發展。

This dedication not only positions us at the cutting edge of health care industry but also ensures that we are effectively meeting the changing needs of our customers. Bending on this foundation, our enhanced financial position allows us to further invest in these innovative offerings ensuring we continue to meet our clients' evolving needs and capitalize on emerging market opportunities.

這種奉獻精神不僅使我們處於醫療保健行業的前沿，而且確保我們有效地滿足客戶不斷變化的需求。在此基礎上，我們增強的財務狀況使我們能夠進一步投資於這些創新產品，確保我們繼續滿足客戶不斷變化的需求並利用新興市場機會。

Syra has began in 2020 by staffing licensed health professionals and behavior and mental health as a part of our health care workforce capability. Building on our expertise and recognizing the urgent need in this area, we have evolved into a health care technology company with the launch of Syrenity, a comprehensive mental health app and other health care products.

Syra 從 2020 年開始，配備有執照的健康專業人員，並將行為和心理健康作為我們醫療保健勞動力能力的一部分。憑藉我們的專業知識並認識到該領域的迫切需求，我們已發展成為一家醫療保健技術公司，推出了全面的心理健康應用程式 Syrenity 和其他醫療保健產品。

Beyond mental health, our digital health business unit offers Syra bot, an innovative AI-backed chatbot, designed to enhance user engagement and streamline health care interaction. Its pre-generated design ensures compliance with regulatory standards, making it an effective solution for various health care providers.

除了心理健康之外，我們的數位健康業務部門還提供 Syra bot，這是一種創新的人工智慧支援的聊天機器人，旨在增強用戶參與度並簡化醫療保健互動。其預先產生的設計確保符合監管標準，使其成為各種醫療保健提供者的有效解決方案。

In our Population Health business unit, we were awarded a contract under the Bipartisan Safer Communities Act, focusing on enhancing mental health services for children and families. This initiative involves conducting a comprehensive assessment of emergency preparedness plans at 8 behavioral health centers in Wyoming followed by tailored recommendations to strengthen their services.

在我們的人口健康業務部門，我們根據兩黨更安全社區法案獲得了一份合同，重點是加強兒童和家庭的心理健康服務。該舉措包括對懷俄明州 8 個行為健康中心的緊急準備計劃進行全面評估，然後提出客製化建議以加強其服務。

Our Health Education business unit is dedicated to improving health education for both patients and providers. Recently, we secured a $6 million contract with Indiana family and social services administration to train health care professionals in community-based settings over the next 4 years. This initiative includes protium development and the quality improvement plans to ensure consistent competencies among support professionals.

我們的健康教育業務部門致力於改善病患和提供者的健康教育。最近，我們與印第安納州家庭和社會服務管理局簽訂了一份價值 600 萬美元的合同，在未來 4 年內培訓社區環境中的醫療保健專業人員。該計劃包括 Protium 開發和品質改進計劃，以確保支援專業人員的能力一致。

Finally, our health care workforce business unit continues to generate steady revenue, recently winning contracts in Delaware, Florida and Kansas. Together, these business units underscore Syra Health's commitment to enhancing health care delivery and improving outcomes through innovative solutions and strategic partnerships.

最後，我們的醫療保健勞動力業務部門繼續產生穩定的收入，最近贏得了特拉華州、佛羅裡達州和堪薩斯州的合約。這些業務部門共同強調了 Syra Health 透過創新解決方案和策略合作夥伴關係加強醫療保健服務和改善結果的承諾。

I would like to take a moment to highlight that in September, we successfully completed a capital raise generating gross proceeds of $2.1 million. Although this capital raise was not a mandatory requirement for the company, it was executed strategically. We pursue this opportunity to bolster our financial flexibility and further support our growth initiatives. With that, let me turn over to our CFO, Priya Prasad, who will walk through the financial details. Priya?

我想花點時間強調一下，9 月份，我們成功完成了融資，產生了 210 萬美元的總收益。儘管本次融資不是公司的強制性要求，但它是策略性執行的。我們抓住這個機會來增強我們的財務靈活性並進一步支持我們的成長計劃。接下來，讓我請我們的財務長 Priya Prasad 來介紹財務細節。普里亞？

Thank you, Deepika. And let me add my warm welcome to everyone joining on this call. The financial results for the third quarter are provided in detail within our press release, which we issued earlier this morning and in our 10-Q.

謝謝你，迪皮卡。請允許我對參加本次電話會議的所有人表示熱烈歡迎。第三季的財務業績在我們今天早上早些時候發布的新聞稿和 10 季報告中詳細提供。

Total revenues for the third quarter of 2024 were $2.3 million compared to $1.6 million in the third quarter of last year, representing 42% growth. Growth was driven by our population health, health care workforce and behavioral and mental health business unit.

2024 年第三季的總營收為 230 萬美元，而去年第三季為 160 萬美元，成長 42%。成長是由我們的人口健康、醫療保健勞動力以及行為和心理健康業務部門推動的。

I will now go through each business unit in detail. Within our Population Health business unit, revenues were $560,000 in the third quarter versus $413,000 in the same period last year, growth of more than 36% driven by continued demand for public health services by government health agencies.

我現在將詳細介紹每個業務部門。在我們的人口健康業務部門中，第三季的收入為 56 萬美元，而去年同期為 41.3 萬美元，由於政府衛生機構對公共衛生服務的持續需求，增加了 36% 以上。

Our health care workforce business unit also experienced strong growth in the third quarter with revenues of $1.6 million compared to $1 million, a growth of 54%. The increase in health care workforce revenue was driven by new customers and contract renewals.

我們的醫療保健勞動力業務部門在第三季也經歷了強勁成長，營收從 100 萬美元增至 160 萬美元，成長了 54%。醫療保健勞動力收入的成長是由新客戶和合約續約推動的。

Our behavioral and mental health business unit posted revenues of [$13,250] compared to [$3,668] in the same period last year. We anticipate further growth in this business unit due to the broader availability of Serenity as a direct-to-consumer product. Within our digital health business unit, revenues were [$92,000] during the third quarter, driven by sales of Syra bot.

我們的行為和心理健康業務部門公佈的收入為 [13,250 美元]，而去年同期為 [3,668 美元]。由於 Serenity 作為直接面向消費者的產品的廣泛可用性，我們預計該業務部門將進一步成長。在 Syra 機器人銷售的推動下，我們的數位健康業務部門第三季營收為 [92,000 美元]。

Gross profit in the third quarter of 2024, was $668,298 compared to $554,541 in the third quarter of 2023, an increase of 21%. Gross profit margins in the third quarter of 2024 was 35% compared to 30% in the third quarter of 2023, attributed to the bulk of the revenue recognition in third quarter of 2023 from the milestone-based implementation of our first digital health product.

2024 年第三季的毛利為 668,298 美元，較 2023 年第三季的 554,541 美元成長 21%。2024 年第三季的毛利率為 35%，而 2023 年第三季為 30%，這歸因於 2023 年第三季收入確認的大部分來自我們首款數位健康產品的基於里程碑的實施。

Gross profit margins in the third quarter of 2024 was 29.7% compared to 17.8% in the second quarter of 2024. The 1,190 basis points increase in gross margin quarter-over-quarter was primarily driven by cost-saving initiatives and enhanced operational efficiencies achieved by adopting a lean approach and reducing redundancies.

2024年第三季的毛利率為29.7%，而2024年第二季的毛利率為17.8%。毛利率較上季成長 1,190 個基點，主要是由於成本節約措施以及透過採用精益方法和減少裁員而提高的營運效率。

Total operating expenses for the third quarter of 2024 were $1.1 million compared to $897,557 in the third quarter of 2023, but down considerably from the second quarter of 2024, when operating expenses totaled $1.7 million, due to our streamlined operations and optimized workforce initiatives, which we expect to continue.

2024 年第三季的總營運費用為110 萬美元，而2023 年第三季為897,557 美元，但與2024 年第二季的營運費用總額170 萬美元相比大幅下降，原因是我們精簡了營運和優化了勞動力計劃，我們期望繼續下去。

Salaries and benefits remained flat in third quarter of 2024 versus third quarter of 2023. Professional fees increased 161% due to the cause of running a public company. Selling, general and administrative expenses increased 23% in advance of recent cost reductions. Depreciation expense was [$25,541] compared to [$12,357], reflecting expanded office space and additional office equipment.

2024 年第三季的薪資和福利與 2023 年第三季持平。由於經營上市公司的原因，專業費用增加了 161%。在近期成本削減之前，銷售、一般和管理費用增加了 23%。折舊費用為 [25,541 美元]，而 [12,357 美元] 則反映了辦公空間的擴大和辦公設備的增加。

R&D expenses were [$34,821], reflecting the continued development of our technology-based solutions. Net loss for the third quarter of 2024 was a negative [$417,535] compared to a negative [$354,376] in the third quarter of 2023, but down a significant 69% since the second quarter of 2024, where the loss was a negative $1.4 million.

研發費用為 [34,821 美元]，反映了我們基於技術的解決方案的持續開發。與2023 年第三季的負值[354,376 美元] 相比，2024 年第三季的淨虧損為負值[417,535 美元]，但自2024 年第二季的負值140 萬美元以來，淨虧損大幅下降69%。

Net loss per share decreased to a negative $0.06 in the third quarter of 2024 from a negative $0.21 in the second quarter of 2024. Adjusted EBITDA for the third quarter of 2024 was a negative [$389,000] compared to a negative [$327,839] in the third quarter of 2023. Cash on hand on September 30, 2024, was $2.7 million. The projections indicate an approximate 2-year capital runway. Again, full reconciliations are provided in the tables included in today's press release.

每股淨虧損從 2024 年第二季的負 0.21 美元降至 2024 年第三季的負 0.06 美元。2024 年第三季調整後 EBITDA 為負值 [389,000 美元]，而 2023 年第三季為負 [327,839 美元]。截至 2024 年 9 月 30 日，手頭現金為 270 萬美元。預測顯示資本跑道大約需要兩年。今天的新聞稿中的表格再次提供了完整的調節結果。

With that, let me turn the call back over to Deepika.

接下來，讓我把電話轉回迪皮卡。

Thank you, Priya. Building on our impressive growth and strategic advancements, we are poised for continued success in the coming quarters. Our strong performance in high-margin business units has solidified our position in critical factors with increasing demand. With the successful launch of our Mental Health app, Syrenity, we are tapping into expanding national and global markets for mental and behavior health solutions, with the need for innovative evidence-based interventions continues to grow.

謝謝你，普里亞。基於我們令人印象深刻的成長和策略進步，我們準備在未來幾季繼續取得成功。我們在高利潤業務部門的強勁表現鞏固了我們在需求成長的關鍵因素中的地位。隨著我們的心理健康應用程式 Syrenity 的成功推出，我們正在開拓不斷擴大的國內和全球心理和行為健康解決方案市場，同時對基於證據的創新幹預措施的需求不斷增長。

Looking ahead, we are committed to driving revenue growth through the expansion of our service offerings and the execution of key contracts in multiple states. The health care workflows and training sectors remain a focus as we deepen our partnerships and increase our presence in new markets.

展望未來，我們致力於透過擴大我們的服務範圍和在多個州執行關鍵合約來推動收入成長。隨著我們深化合作夥伴關係並擴大在新市場的影響力，醫療保健工作流程和培訓領域仍然是重點。

We are also keen to explore and expand our presence in federal markets leveraging our expertise to meet the growing needs of government agencies focused on health and public welfare. This will further strengthen our portfolio and position us as a trusted partner in large-scale federal initiatives.

我們也熱衷於探索和擴大我們在聯邦市場的影響力，利用我們的專業知識來滿足專注於健康和公共福利的政府機構不斷增長的需求。這將進一步加強我們的產品組合，並使我們成為大規模聯邦計畫中值得信賴的合作夥伴。

Importantly, our ongoing cost-saving initiatives have resulted in a sustainable reduction in operating expenses, allowing us to optimize resources while maintaining high-quality service delivery. We remain focused on enhancing operational efficiency and leveraging AI technology to support long-term growth.

重要的是，我們持續的成本節約措施實現了營運費用的可持續減少，使我們能夠優化資源，同時保持高品質的服務交付。我們仍然專注於提高營運效率並利用人工智慧技術來支援長期成長。

With a narrowed net loss, improved gross margins and the strengthened operational strategy, the company is poised for growth, reporting a solid 2-year capital runway. With these efforts, we are optimistic about the potential to achieve profitability by 2025 and to scale our impact in health care innovation, continuing to deliver value to our clients, stakeholders and communities. I thank you for your attention. I'm happy to take any questions you may have. Robert?

隨著淨虧損收窄、毛利率提高和營運策略強化，該公司已做好成長準備，並報告了穩定的兩年資本跑道。透過這些努力，我們對 2025 年實現盈利的潛力持樂觀態度，並擴大我們在醫療保健創新方面的影響力，繼續為我們的客戶、利害關係人和社區創造價值。我感謝您的關注。我很樂意回答您的任何問題。羅伯特？

Thank you to the management team. We have some questions for you. First, what was the objective behind the capital raise you conducted in the third quarter?

感謝管理團隊。我們有一些問題想問你。首先，你們第三季進行融資的目的是什麼？

Yes, Robert. The recent capital raise was executed strategically and it was not a mandatory requirement for the company. We pursued this opportunity to enhance our financial flexibility and support our growth initiatives.

是的，羅伯特。最近的融資是策略性的，並不是公司的強制性要求。我們抓住這個機會來增強我們的財務靈活性並支持我們的成長計劃。

Okay. Great. Next question, can you provide any updates on Syrenity?

好的。偉大的。下一個問題，您能提供 Syrenity 的任何更新嗎？

Most definitely. Syrenity is our unique scientifically validated and a comprehensive mental app, which has a dual focus on prevention and intervention. It's one of the many Mental Health apps available where it is one of less than 5% that is based on signs.

絕對是。Syrenity 是我們獨特的經過科學驗證的綜合心理應用程序，它雙重關注預防和介入。它是眾多可用的心理健康應用程式之一，其中基於體徵的應用程式不足 5%。

Sophisticated algorithms provide risk scores for various mental health conditions and the app also suggests tailored interventions. Syrenity also includes a direct link for suicide prevention where immediate support is needed. The early feedback we have been receiving from our customers, it's been very encouraging, and we are excited about the potential this product holds.

複雜的演算法提供各種心理健康狀況的風險評分，該應用程式還建議量身定制的干預措施。Syrenity 還包括與需要立即支持的自殺預防的直接聯繫。我們從客戶收到的早期回饋非常令人鼓舞，我們對該產品的潛力感到興奮。

Okay. Great. And our final question is tell me about your approach to integrating AI in your technology products?

好的。偉大的。我們的最後一個問題是告訴我你們將人工智慧整合到你們的科技產品中的方法？

Yes. Definitely. By integrating AI in our proprietary guardrails technology, we are leading the change in creating AI systems that are not only powerful and efficient but also ethical and transparent. Syra guardrails is an explainable AI framework that ensures AI-generated responses are safe, nonjudgmental and compliant with health care regulations.

是的。確實。透過將人工智慧整合到我們專有的護欄技術中，我們正在引領變革，創建不僅強大、高效，而且道德和透明的人工智慧系統。Syra Guardrails 是一個可解釋的人工智慧框架，可確保人工智慧產生的回應是安全的、不帶偏見的並且符合醫療保健法規。

Unlike traditional AI, which operates as a black box, our guardrails technology is designed to be transparent and explainable allowing users and health care providers to understand and trust AIS decisions. Whether it's a hospital chatbot that needs to avoid giving medical advice, or an AI journal that must be within regulatory guidelines. Syra guardrails ensures that the AI remains on task and within defined ethical boundaries.

與作為黑盒子運作的傳統人工智慧不同，我們的護欄技術旨在透明且可解釋，使用戶和醫療保健提供者能夠理解和信任 AIS 決策。無論是需要避免提供醫療建議的醫院聊天機器人，還是必須遵守監管指南的人工智慧期刊。Syra 護欄可確保人工智慧繼續執行任務並遵守規定的道德界限。

Okay. It looks like we are out of time. My thanks to everyone for participating in today's call. We look forward to speaking with all of you again next quarter.

好的。看來我們已經沒時間了。我感謝大家參加今天的電話會議。我們期待下個季度再次與大家交談。